MPLT · MapLight Therapeutics, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on MPLT. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About MPLT · MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.
Live Quote
HOLD (score +1) · 12-1 mom 59.7% · RSI 50 · below_both · -10.9% from high
Targets blend Wall Street consensus (10 analysts: low $30.00 / mean $39.20 / high $48.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
MapLight is a pre-revenue CNS biotech with ~$305M cash burning at ~$83M/year. The investigation trigger was 4 Form 4 filings in 14 days — but every single filing reviewed shows systematic SELLING under Rule 10b5-1 plans adopted Dec 29, 2025 by the CEO (Kroeger), CSO (Lillie), and GC (Hanson). Kroeger's sales alone total ~$3M+ in May. Zero open-market P transactions exist in this cluster; no insider has purchased in any recent filing reviewed. The bullish trigger is entirely explained by scheduled diversification plans, not conviction buying. Near-term catalysts exist: ZEPHYR Phase 2 schizophrenia data and IRIS Phase 2 autism data both expected mid-August 2026, plus Q1 earnings May 14. Two analyst Buy initiations (TD Cowen $45 target, Needham $37). No options chain exists — income strategies are unavailable.